Biosimilars

Brain Cancer

Breast Cancer

Business Management

CAR T-cell Therapy

COVID-19

Chronic Lymphocytic Leukemia

Colorectal Cancer

Disparities in Cancer Care

Gastrointestinal Cancer

Genitourinary Cancers

Global Oncology

Gynecologic Oncology

Head & Neck Cancers

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Mantle Cell Lymphoma

Melanoma & Skin Cancer

Multiple Myeloma

Myeloproliferative Neoplasms

Neoadjuvant HER2+

Non-Hodgkin Lymphoma

Oncology Nursing News

Ovarian Cancer

Pediatric Oncology

Precision Medicine in Oncology®

Prostate Cancer

Sarcomas/TGCT

Supportive Care

Urothelial Cancer

To continue making progress in lung cancer treatment, investigators must keep pushing the science in new directions even as immunotherapy becomes more available in earlier lines.

Immunotherapy Must Become More Precise and Personalized

Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.

Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.

Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

As more agents are evaluated either in addition to or following PD-1/PD-L1 inhibitors, more information may be learned about how best to leverage alternate biomarkers, according to Marina C. Garassino, MD.

PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

OncologyLive

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Subscribe

Print Subscription

eNewsletter


Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for 

 and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: 

Articles

With 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.

Raising the Bar for KRAS G12C Colorectal Cancer Treatment

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: 

Avero Diagnostics has launched AMBLor, a first-of-its-kind laboratory test for the identification of early-stage melanoma at low risk of progression. 

Launch of AMBLor Test Enables Risk Stratification in Early-Stage Melanoma 

Cardiovascular diseases are the follow-up threats many men face after undergoing androgen deprivation therapy, also known as hormonal treatment, for prostate cancer.

$1.1 Million Department of Defense Grant Supports Augusta University Research Linking Prostate Cancer and Cardiovascular Diseases

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

F. Anthony Greco, MD, Sarah Cannon Cancer Center

Articles

Latest Conference Coverage